ABSTRACT
INTRODUCTION The incidence of diabetes in the U.S. is increasing with at least 1 million persons
affected with type 1 disease.1 The life threatening complications2 are preventable by maintaining euglycemia according to the Diabetes Control and Complication Trial and its follow-up studies.3,4 Despite the development of improved means of glucose monitoring and insulin delivery, maintaining even near-normal glucose levels in most patients with diabetes is difficult and complicated by occasional severe hypoglycemic episodes. Developing a means of achieving insulin independence and good glycemic control early in the disease prior to the onset of complications would represent a major therapeutic advance in the treatment of this debilitating disease.
